相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Ultragenyx and Mereo BioPharma announced results from two Phase 3 studies evaluating setrusumab, a sclerostin-inhibiting monoclonal antibody, for treating osteogenesis imperfecta in pediatric patients. - The ORBIT study enrolled 159 patients aged 5-25 years across 45 sites in 11 countries, comparing setrusumab to placebo with annualized clinical fracture rate as the primary endpoint. - The COSMIC study enrolled 69 patients aged 2-7 years across 21 sites in 7 countries, comparing setrusumab to intravenous bisphosphonates therapy. - Setrusumab targets an unmet medical need in osteogenesis imperfecta, a rare genetic bone disorder affecting approximately 60,000 people globally with no currently approved treatments.
- The FDA has postponed its decision on a gene therapy treatment for Sanfilippo syndrome, pushing potential approval to February 2026 due to additional clinical data review requirements. - The treatment would be the first available for children with this type of Sanfilippo syndrome, a rare genetic disorder also known as childhood Alzheimer's that causes progressive cognitive decline. - Six-year-old Emmett Doucette and other affected families are advocating for approval, as the delay raises concerns about disease progression during the extended review period. - The gene therapy has received orphan drug, rare pediatric disease, and regenerative medicine advanced therapy designations from the FDA despite the approval delay.
- Up to 3,500 FDA staffers received termination notices following a Supreme Court ruling that found the government's HHS overhaul to be lawful. - FDA Commissioner Marty Makary proposed lowering prescription drug user fees and offering speedier reviews to companies willing to reduce drug costs. - The agency released over 200 complete response letters for transparency, revealing rejection rationales for previously approved therapies including Eli Lilly's Alzheimer's drug Kisunla. - Two rare disease therapy rejections were issued to Ultragenyx for Sanfilippo syndrome type A and Capricor Therapeutics for DMD-associated cardiomyopathy.
- Two major European gene therapy summits are addressing critical analytical and quality control challenges following recent regulatory setbacks, including Rocket Pharma's KRESLADI rejection that exposed CMC vulnerabilities. - The 6th Gene Therapy Analytical Development Summit Europe will bring together 24+ expert speakers and over 90 industry stakeholders to tackle analytics across the gene therapy lifecycle from Pre-IND/IMPD to BLA. - The inaugural Gene Therapy Potency Summit focuses specifically on potency assay challenges during the critical "sweet spot" of drug development from pre-clinical through commercialization. - Both events feature leading companies including Sarepta Therapeutics, Biogen, Sanofi, and regulatory experts from MHRA to provide practical solutions for assay validation and regulatory compliance.
• REGENXBIO has closed a non-dilutive royalty bond agreement with Healthcare Royalty for up to $250 million, receiving $150 million upfront that extends its cash runway into early 2027. • The deal monetizes select royalties from ZOLGENSMA for SMA and payments from gene therapies for MPS disorders, while REGENXBIO retains other funding opportunities including a potential Priority Review Voucher. • This strategic financing supports REGENXBIO's late-stage pipeline development, including RGX-121 for MPS II, RGX-202 for Duchenne muscular dystrophy, and ABBV-RGX-314 for wet AMD.
- Ionis Pharmaceuticals is moving forward with Phase 3 trials for ION582, an antisense therapy designed to unsilence the paternal UBE3A gene in Angelman syndrome patients, after Biogen declined to license the drug. - In the Phase 1/2 HALOS study, 97% of participants receiving medium or high doses of ION582 showed improvements in communication, cognition, and motor function, with favorable safety profiles. - The race to develop treatments for Angelman syndrome is intensifying, with Ultragenyx's GTX-102 already in Phase 3 trials and Neuren Pharmaceuticals advancing an oral synthetic peptide, highlighting significant progress in addressing this rare genetic disorder.
• Ultragenyx reported preliminary 2024 revenue of $555 million to $560 million, exceeding previous guidance, driven by strong sales of Crysvita and Dojolvi. • The company anticipates total revenue between $640 million and $670 million in 2025, projecting continued growth and pipeline advancement. • Key clinical programs are progressing, including setrusumab for osteogenesis imperfecta (Phase 3) and GTX-102 for Angelman syndrome (Phase 3). • Ultragenyx expects a PDUFA decision for UX111 in Sanfilippo syndrome type A and plans to file a BLA for DTX401 in Glycogen Storage Disease Type Ia in 2025.
• Ultragenyx has commenced the Phase 3 Aspire study to evaluate GTX-102, an experimental treatment for Angelman syndrome, in children aged 4 to 17. • The Aspire study is a randomized, sham-controlled trial with a 48-week primary efficacy analysis period, measuring cognitive improvement via the Bayley-4 cognitive raw score. • Ultragenyx is also anticipating an interim analysis from the Phase 3 Orbit study for setrusumab, expected around the end of 2024 or early 2025. • Analysts maintain a strong buy consensus on Ultragenyx stock, with price targets ranging from $48 to $140 per share, reflecting optimism about the company's pipeline.
- Ultragenyx has initiated the Phase 3 Aspire study to evaluate GTX-102 for Angelman syndrome, a rare neurogenetic disorder. - The Aspire study will enroll 120 children aged 4-17 with Angelman syndrome, assessing cognitive and motor function improvements. - GTX-102 is an investigational antisense oligonucleotide designed to restore UBE3A protein expression by targeting UBE3A-AS. - The Aurora study is planned for 2025 to evaluate GTX-102 in other Angelman syndrome genotypes and age groups.
- The FDA has granted priority review to Ultragenyx's Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). - The FDA's decision is expected by August 18, 2025, and the agency is not planning an advisory committee meeting for this application. - UX111 has demonstrated statistically significant improvements in cognitive and communication skills, correlated with reduced heparan sulfate levels in cerebrospinal fluid. - UX111, if approved, would be the first-ever treatment for Sanfilippo syndrome type A, addressing a critical unmet need for this rare, neurodegenerative disease.
